COMPANY PROFILE

Ikaria

Explore full profile

Develop and deliver innovative therapeutics and interventions to meet the significant needs of critically

Hampton Township, United StatesFounded 2007Biotech & Life Sciences

Valuation $1–2.5B Last recorded · 2015

Revenue $100–500M Latest reported FY

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Ikaria

Ikaria Inc. operated as a fully-integrated biotherapeutics company with a dedicated focus on the critical care market. The company was incorporated in Delaware in August 2006, initially as ITL Holdings, Inc., before changing its name to Ikaria Holdings, Inc. in 2007 and finally to Ikaria, Inc. in 2010. The modern iteration of the company was shaped by the 2007 merger between the legacy Ikaria, Inc. and INO Therapeutics LLC. David Shaw was the founding CEO, later serving as executive chair.

Read full description

The firm’s business centered on developing and commercializing innovative therapies and interventions for critically ill patients, primarily within the hospital setting. Its flagship product was the INOMAX® therapy package, an all-inclusive offering that combined the INOMAX® (nitric oxide) drug for inhalation with a proprietary drug-delivery system, comprehensive on-site training for clinicians, and continuous 24/7 technical support. This integrated model positioned Ikaria as a key partner to hospitals, particularly in neonatal intensive care units (NICUs).

The primary application for INOMAX is as the only FDA-approved treatment for term and near-term newborn babies experiencing hypoxic respiratory failure connected with pulmonary hypertension. The therapy functions as a vasodilator to improve oxygenation and critically reduces the need for extracorporeal membrane oxygenation (ECMO), a complex and invasive life-support procedure. The company's revenue was driven by the sale of this bundled drug, device, and service package. A significant milestone in the company's history occurred in April 2015, when it was acquired by Mallinckrodt plc for approximately $2.3 billion. This acquisition was a strategic move for Mallinckrodt to bolster its hospital portfolio and expand its footprint into the specialized field of neonatal critical care.

Source: Dealroom company data